This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Investigational Compounds

We are dedicated to delivering first-in-class cancer cell directed therapies, innovations in immuno-oncology and smart therapeutic combinations.

Find out more about our clinical development programme, below.

Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.

Video
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Video
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Video
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Video
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick

Did you find this information useful?

Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063 and BI 1361849 are investigational compounds and have not been approved. Their safety and efficacy have not been established.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: June 2019